[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,229
  • Shares Outstanding, K 3,939
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,970 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.28
  • Price/Sales 11.04
  • Price/Cash Flow N/A
  • Price/Book 1.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.07
  • Number of Estimates 2
  • High Estimate $-1.01
  • Low Estimate $-1.13
  • Prior Year $-1.08
  • Growth Rate Est. (year over year) +0.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.76 +14.06%
on 08/14/26
36.52 -10.19%
on 08/11/26
+1.78 (+5.74%)
since 07/27/26
3-Month
28.76 +14.06%
on 08/14/26
38.84 -15.55%
on 06/30/26
-0.92 (-2.73%)
since 05/27/26
52-Week
17.00 +92.94%
on 09/02/25
44.00 -25.45%
on 01/06/26
+16.56 (+101.97%)
since 08/27/25

Most Recent Stories

More News
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.44 (+0.74%)
SER : 2.52 (-4.18%)
GANX : 1.8500 (+2.21%)
BIOA : 10.08 (+2.44%)
OSTX : 1.6800 (+1.82%)
VTVT : 32.80 (-2.29%)
MASS : 11.10 (+7.04%)
PYPD : 5.12 (+0.20%)
TKNO : 7.31 (+1.25%)
OVID : 2.93 (+1.74%)
MDCX : 0.2678 (-0.26%)
EQ : 2.45 (+3.81%)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of  cadisegliatin , a novel, potential first-in-class...

VTVT : 32.80 (-2.29%)
VTv Therapeutics: Q2 Earnings Snapshot

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 32.80 (-2.29%)
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

VTVT : 32.80 (-2.29%)
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid...

VTVT : 32.80 (-2.29%)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of  cadisegliatin , a novel, potential first-in-class...

VTVT : 32.80 (-2.29%)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the...

VTVT : 32.80 (-2.29%)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the...

VTVT : 32.80 (-2.29%)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class...

VTVT : 32.80 (-2.29%)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of  cadisegliatin , a novel, potential first-in-class...

VTVT : 32.80 (-2.29%)

Business Summary

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical...

See More

Key Turning Points

3rd Resistance Point 35.26
2nd Resistance Point 34.68
1st Resistance Point 33.74
Last Price 32.80
1st Support Level 32.21
2nd Support Level 31.63
3rd Support Level 30.69

See More

52-Week High 44.00
Fibonacci 61.8% 33.69
Last Price 32.80
Fibonacci 50% 30.50
Fibonacci 38.2% 27.31
52-Week Low 17.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.